EDUARDO NOVOA CIANELLI: Open Payments
NPI 1992302756 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$751 in 18 payments from 11 companies in 2025. Trend: 2023 $249 · 2024 $209 · 2025 $751
Food & beverage: $751
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $228 |
| GlaxoSmithKline, LLC. | 2 | $142 |
| SOBI, INC | 3 | $93 |
| Geron Corporation | 3 | $61 |
| Blueprint Medicines Corporation | 2 | $57 |
| Adaptive Biotechnologies Corporation | 1 | $45 |
| Celgene Corporation | 1 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $21 |
Products named: SCEMBLIX, OJJAARA, RYTELO, Doptelet, AYVAKIT, clonoSEQ, Vonjo, REBLOZYL.
Industry payments across FL — which companies pay providers there.
